Karim Qumosani

QumosaniKpic115150.jpg

Contact Information

University Hospital, 339 Windermere Road, London, Ontario N6A 5A5, Rm A10-227
Tel: 519.663.3976
Fax: 519.663.2907

Research Interests/Specialization

Liver Transplantation

Dr. Karim Qumosani is an Associate Professor of Medicine at Western University. Currently, he is the Program Director for the Gastroenterology Residency Training Program and the Area of Focused Competence Adult Hepatology Fellowship Diploma Program. Dr. Qumosani is proud to lead both training programs as, the Gastroenterology and Hepatology Program at Western University was recently recognized as one of the Best Global Universities for Gastroenterology and Hepatology by U.S. News, scoring the second highest rank in Canada and 22nd world wide.

Dr. Qumosani completed his MD at King Abdulaziz University and his Internal Medicine Residency, Gastroenterology Fellowship and Advanced Hepatology and Liver Transplantation Fellowship at Western University.

Dr. Qumosani joined the Division of Gastroenterology at Western University in 2013 and has widespread involvement in medical education at the undergraduate and postgraduate levels of training. He has a strong passion for teaching and mentoring. Clinically, his expertise is in liver transplantation, hepatocellular carcinoma and immune mediated liver disease. His research focuses primarily on hepatocellular carcinoma and immune mediate liver disease.

Selected Publications

Aziz S, Sey M, Marotta P, Driman D, Parfitt J, Teriaky A, Brahmania M, Skaro A, Qumosani K. Recurrent Hepatocellular Carcinoma After Liver Transplantation: Validation of a Pathologic Risk Score on Explanted Livers to Predict Recurrence. Transplant Proc, 2021 Jul 13, Senior Responsible Author, DOI: 10.1016/j.transproceed.2021.05.007.

Qumosani K, Aziz S, Sey M, Marotta P, Driman D, Parfitt J, Teriaky A, Brahmania M, Skaro A. Recurrent hepatocellular carcinoma after liver transplantation: Validation of a pathological risk score on explanted livers to predict recurrence. Transplantation Proceedings, 2021 May 10, Senior Responsible Author

Alsager M, Neong SF, Gandhi R, Teriaky A, Tang E, Skaro A, Qumosani K, Lilly L, Galvin Z, Selzner N, Bhat MP, Puka K, Brahmania M. Liver transplantation in adult polycystic liver disease: the Ontario experience. BMC Gastroenterol, 2021 Mar 9; 21 (1): 115, Coauthor, DOI: 10.1186/s12876-021-01703-x.

Kumar S, Qumosani K,Taylor T, Sun D. Primary Sclerosing Cholangitis: a New Case of Cirrhosis in Pregnancy. Obstetric Medicine, 2020 Dec 8, Coauthor

Chande N, Qumosani K, Thomson A. Medical Mini Review Series in Gastroenterology and Hepatology Volume 6: Efficient Refresher for the Busy Clinical Gastroenterologist. 2020 Sep CreateSpace Independent Publishing Platform, Coauthor

Alghamdi W, Qumosani K, Brahmania M, Marotta P, Skaro A, Teriaky A. Hepatitis C Positive Organ Transplantation to Negative Recipients at a Multiorgan Canadian Transplant Centre: Ready for Prime Time. Journal of Hepatology, 2020 Aug, Coauthor, DOI: 10.1016/S0168-8278(20)31227-7.

Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, McKenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. American Journal of Gastroenterol, 2020 May 15, Coauthor, DOI: 10.14309/ajg.0000000000000661.

Al-Judaibi B, Alqalami I, Sey M, Qumosani K, Howes N, Sinclair L, Chandok N, Eddin AH, Hernandez-Alejandro R, Marotta P, Teriaky A. Exercise Training for Liver Transplant Candidates. Transplantation Proceedings, 2019 Dec 1; 51 (10): 3330-3337, Coauthor, DOI: 10.1016/j.transproceed.2019.08.045.

Wong F, Al Ibrahim B, Walsh J, Qumosani K. Infliximab-induced autoimmune hepatitis requiring liver transplantation. 2019 Nov 1 Clinical Case Reports, Coauthor, DOI: 10.1002/ccr3.2456.

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis, 2019 Oct 28; 26 (6): 949-959, Coauthor, DOI: 10.1093/ibd/izz244.

Teriaky A, Mosli M, Chandok N, Al-Judaibi B, Marotta P, Qumosani K. Prevalence of fat-soluble vitamin (A, D, and E) and zinc deficiency in patients with cirrhosis being assessed for liver transplantation. Acta Gastroenterol Belg, 2017 Apr 1; 80 (2): 237-241, Coauthor

Qumosani K. Congenital Liver Diseases. In:Thomson A and Al-Judaibi B, editor(s). Medical Mini Review Series in Hepatology Volume 4: Efficient Refesher for the Busy Clinical Gastroenterologist. 4: CreateSpace Independent Publishing Platform; 2017, Principal Author

Alghanem M, Driman D, Bashir O, Al Judaibi B, Kakani N, Marotta P, Qumosani K. Hepatocellular Carcinoma Response to Local Regional Therapy; Correlations Between Pre-Liver Transplant Imaging and Explant Pathology. Journal of Gastrointestinal and Digestive System, 2016 Jun 29; 6 (3), Principal Author